Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study.
Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli Ö, Maceski A, Oechtering J, Achtnichts L, Conen D, Derfuss T, Lalive PH, Mueller C, Müller S, Naegelin Y, Oksenberg JR, Pot C, Salmen A, Willemse E, Kockum I, Blennow K, Zetterberg H, Gobbi C, Kappos L, Wiendl H, Berger K, Sormani MP, Granziera C, Piehl F, Leppert D, Kuhle J; NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group.
Benkert P, et al.
Lancet Neurol. 2022 Mar;21(3):246-257. doi: 10.1016/S1474-4422(22)00009-6.
Lancet Neurol. 2022.
PMID: 35182510
However, longitudinal sNfL Z scores remained elevated with platform compounds (interferons and glatiramer acetate; p<0.0001 for the interaction term between treatment category and treatment duration). Results were fully supported in the validation cohort (n=4341) from t …
However, longitudinal sNfL Z scores remained elevated with platform compounds (interferons and glatiramer acetate; p<0.0001 for the inter …